In a report released yesterday, Ryan Zimmerman from BTIG reiterated a Buy rating on Avita Medical (RCEL – Research Report), with a price target of $16.00. The company's shares closed last Thursday at $5.64, close to its 52-week low of $5.06. According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 10.5% and a 44.1% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Treace Medical Concepts, and Organogenesis Holdings. Avita Medical has an analyst consensus of Moderate Buy, with a price target consensus of $15.50.
https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-avita-medical-rcel?utm_source=advfn.com&utm_medium=referral
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From May 2022 to Jul 2022 Click Here for more Avita Medical Charts.
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Avita Medical Charts.